Eli Lilly Archives

News and Trends 9 Nov 2015

This French Biotech has a ‘Super-Insulin’ up its Diabetes Sleeve

Human insulin produced in Bacteria is already a miracle for Diabetes…but sometimes, it’s not as efficient as it could be. The French Biotech Adocia is developing a super-insulin and showed successful efficiency data in a early-stage human trials. Adocia is a Lyon-based Biotech we have discussed before. Even if its logo is a bit strange […]

November 9, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Jul 2015

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

Immunocore Limited, just announced that it has secured a £205 million financing (€293 m) from private investors to push forward its T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune diseases. This substantial amount of cash not only embodies the largest private investment ever made in Europe by a biotech company, but also the second […]

July 16, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 3 Jul 2015

Lilly Cooperates with Immunocore to Fight Skin Cancer

Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore‘s lead T cell receptor-based drug, IMCgp100 is tested in combination with Lilly’s kinase inhibitors galunisertib and merestinib. This second collaboration between these two companies aims to increase drug efficacy against melanoma cancer. Melanomas are rare forms of skin cancer, that have a high potential […]

July 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Jul 2015

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

Adocia and Eli Lilly completed an impressive Phase Ib clinical trial evaluating BioChaperone Lispro, a treatment designed to accelerate insulin absorption. The study aimed to compare BioChaperone Lispro to Lilly’s Humalog in type 1 diabetes patients, the former being much more effective. Humalog, Lilly’s blockbuster, is about to be ousted by Adocia’s insulin absorption accelerator. BioChaperone Lispro […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 31 May 2015

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

The big pharma companies Eli Lilly and AstraZeneca will combine two of their cancer drugs to make the perfect cocktail against solid tumors. They have entered a clinical collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor (MEDI4736), in combination with Cyramza (ramucirumab), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. MEDI4736 is […]

May 31, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 14 May 2015

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. Cancers figure […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 Dec 2014

French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly

The French biotechnology company Adocia entered into an alliance with the US Eli Lilly on the co-development of an ultra-fast insulin to treat type 1 and type 2 diabetes. This insuline, called BioChaperone Lispro, has been developed through Adocia’s technology BioChaperone, is currently in Phase Ib clinical study. Under this global license agreement with Adocia, Eli Lilly […]

December 20, 2014 - 2 minutesmins - By Philip Hemme

Eli Lilly and Boehringer Ingelheim’s product the first insulin biosimilar approved in Europe2

News and Trends 16 Sep 2014

The first insulin biosimilar has been approved in Europe

The European Commission granted marketing authorisation to Eli Lilly and Company and Boehringer Ingelheim for the first insulin biosimilar glargine product. It is indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The collaboration between the two companies is bearing fruit, it is the first-ever version of this class. It received […]

September 16, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eli Lilly

This French Biotech has a ‘Super-Insulin’ up its Diabetes Sleeve

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

Lilly Cooperates with Immunocore to Fight Skin Cancer

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly

The first insulin biosimilar has been approved in Europe

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!